drug
ristoglogene autogetemcel
Phase 2updated 6mo agoby $BEAM Beam Therapeutics Inc.
Phase 2community read0 votes
all catalysts(0)
nothing on the calendar yet
News(3)
- Beam’s base editing therapy for sickle cell hits goal in pivotal trialThe result represents a scientific milestone and positions Beam to submit a first-of-its-kind FDA application as soon as the end of the year.biopharma_dive · 9d ago
- Beam preps FDA run for industry-first base-edited therapy after pivotal sickle cell successBeam Therapeutics' risto-cel provided at least 12 consecutive months of freedom from severe pain crises for patients with sickle cell disease in a mid-stage trial, setting the stage for an FDA appl…biospace · 9d ago
- Beam’s sickle cell therapy results tee up potential Casgevy, Lyfgenia showdownGearing up for a potential FDA filing by the end of the year, Beam Therapeutics revealed results from a phase 1/2 study of its base-edited cell therapy risto-cel, showing the potential sickle cell…fiercebiotech · 9d ago
Data sources
last refreshed 7h ago
Found something off?
comments(0)
5-min edit window · permanent after that